If you already take Mounjaro and are thinking about changing providers because of price, stock availability, delivery, or customer service, you are probably asking two simple questions: Can I switch providers safely, and will I have to start again?
This guide answers both questions and explains how Mounjaro bundles work, so you can decide whether ordering multiple pens could help reduce your monthly cost. The aim is to help you make an informed decision about your treatment options.
Switching a prescription only medicine is more than simply placing an order with a different pharmacy. You will need a new clinical assessment, so continuity of care is an important part of the process.
Quick answer (featured snippet style): Yes, you can switch Mounjaro providers in the UK. You will complete a new online consultation with the new pharmacy's prescriber, share your current dose and treatment history, and, if the prescriber decides it is clinically appropriate, you may be able to continue on your current dose instead of starting again at 2.5mg. There is no NHS or manufacturer "transfer form." Each provider carries out its own independent clinical assessment.
What is Mounjaro, and who makes it?
Mounjaro is the brand name for tirzepatide, a once weekly injection made by Eli Lilly and Company. It is a dual GIP and GLP 1 receptor agonist that works on two hormone receptors involved in appetite and metabolic regulation. In the UK, it is licensed by the MHRA for weight management alongside a reduced calorie diet and increased physical activity, and for the treatment of type 2 diabetes.
One common point of confusion is that Mounjaro is made by Eli Lilly, not Novo Nordisk. Novo Nordisk manufactures semaglutide medicines such as Wegovy and Ozempic. This distinction is important when comparing treatments because the clinical evidence for Mounjaro is based on studies of tirzepatide.
You can review the treatment, current strengths, and stock on our Mounjaro injections page, or compare options across our prescription weight loss treatments hub.
How tirzepatide works
Tirzepatide works with your body's natural appetite signals to support weight management. By activating the GIP and GLP 1 receptors, it may:
- Help reduce appetite, which may make it easier to manage portion sizes.
- Slow gastric emptying, which may help you feel fuller for longer after meals.
- Help regulate blood glucose responses, which may reduce the fluctuations that some people associate with feeling hungry between meals.
- Help reduce the constant thoughts about food that many people describe as "food noise."
Together, these effects may make it easier for some people to follow a reduced calorie diet. Mounjaro supports your weight management plan, while healthy eating, regular physical activity, and good sleep habits continue to play an important role. Results vary from person to person, and Mounjaro should only be used under the supervision of an appropriately qualified prescriber.
Can you switch Mounjaro providers? Yes, here is how
Changing providers is common and completely legitimate. Because Mounjaro is a prescription only medicine, your new provider must carry out its own clinical assessment before prescribing it. There is no shortcut around this process, and it is an important part of making sure the treatment remains suitable for you.
How to switch Mounjaro provider, step by step
- Complete a new online consultation with your chosen pharmacy and answer all questions honestly.
- Share details of your current treatment, including your current dose, how long you have been taking Mounjaro, how well you have tolerated it, and whether you have experienced any side effects.
- A UK registered independent prescriber will review your consultation, assess whether the treatment is appropriate for you, and decide whether you can continue on your current dose.
- If your prescription is approved, your medication can be dispensed and delivered using a tracked, temperature controlled delivery service.
Do you need to restart at 2.5mg when you switch? Not always. If your treatment history supports it, the prescriber may decide that it is appropriate for you to continue on your current dose instead of returning to the starting dose. This decision is always based on your clinical assessment. Your prescriber will determine the most appropriate treatment for you.
What information helps make the switch smoother?
Having the following information ready can help make the process quicker:
- Your current Mounjaro dose and how long you have been taking it.
- The date of your most recent injection.
- Details of any side effects or previous dose changes.
- Relevant medical history, current medications, and any allergies.
Reasons people switch, and what to check first
| Common reason to switch | What to actually compare |
|---|---|
| Price feels high | Total cost (medicine + consultation + delivery), not just the headline offer |
| Ran out of stock | Whether your current or anticipated strength is currently available |
| Slow delivery | Dispatch speed and temperature-controlled packaging |
| Poor support | Access to a prescriber/pharmacist if side effects occur |
| Want to buy ahead | Whether bundles are available at your confirmed strength |
Is it safe to switch, and will your treatment continue smoothly?
Yes, switching can be safe when it is done through a GPhC registered pharmacy with an independent prescriber who carries out a clinical assessment and prescribes genuine Eli Lilly Mounjaro.
To help protect your health, avoid buying from unregulated sellers, providers that do not require a clinical assessment, or any source that cannot confirm the medication has been stored and transported using the correct temperature controlled process.
To help avoid interruptions to your treatment, it is a good idea to arrange your next prescription before your current supply runs out. This can help you stay on your usual weekly injection schedule. Your prescriber or pharmacist can advise you on the best timing based on your individual circumstances.
The clinical evidence behind Mounjaro
Mounjaro is supported by evidence from the SURMOUNT clinical trial programme. One of the key studies, SURMOUNT 1, was published in the New England Journal of Medicine. The study included 2,539 adults living with obesity, or who were overweight with a weight related health condition, without type 2 diabetes. Participants received treatment for 72 weeks.
| Weekly dose | Average weight loss (SURMOUNT-1) |
|---|---|
| 5 mg | ~16.0% |
| 10 mg | ~21.4% |
| 15 mg | ~22.5% |
| Placebo | ~2.4% |
Longer term follow up studies have shown that some participants maintained clinically meaningful weight loss while continuing treatment. On heart health, the large SURPASS CVOT trial reported cardiovascular outcomes for tirzepatide in adults with type 2 diabetes in 2025, and the dedicated obesity cardiovascular outcomes study, SURMOUNT MMO, is still ongoing.
These findings come from tirzepatide's own clinical trials. This is an important distinction, as some websites incorrectly refer to results from semaglutide's SELECT study instead. It is also important to remember that the published results are average outcomes seen in clinical trials and should not be taken as a guarantee of individual results.
Who is eligible for Mounjaro?
There are two different routes to accessing Mounjaro, and they are often confused.
Private treatment may be considered for adults who meet the licensed prescribing criteria and are suitable following a clinical assessment. This generally includes adults with:
- a BMI of 30 or above, or
- a BMI of 27 to 29.9 with a weight related health condition, such as high blood pressure, raised cholesterol, sleep apnoea, or prediabetes.
For some ethnic groups, different BMI thresholds may apply in line with recognised clinical guidance.
NHS treatment follows the stricter NICE Technology Appraisal TA1026, published in December 2024. Access is being introduced in phases through primary care, starting with those who have the greatest clinical need. For example, in the first phase, this includes people with a BMI of 40 or above and at least four qualifying health conditions.
Your BMI is only one part of the assessment. Whether Mounjaro is suitable for you depends on your overall health and a clinical review by a prescriber.
You should speak to a prescriber before starting treatment if you are pregnant, trying to become pregnant, breastfeeding, have a history of medullary thyroid cancer, have certain pancreatic or digestive conditions, or are under 18 years of age.
Mounjaro prices and the dose ladder
Mounjaro is a once weekly injection. In the UK, each KwikPen contains four weekly doses, providing a 28 day supply.
Your treatment will usually be reviewed and, where appropriate, adjusted over time by your prescriber. We describe the dose ladder to help you understand how treatment is typically managed, not as dosing advice.
| Strength | Single-pen price (4-week supply) |
|---|---|
| 2.5 mg | £169.99 |
| 5 mg – 12.5 mg | Intermediate strengths — see live checkout pricing |
| 15 mg | £278.99 |
Remove entirely before publication . Remove entirely before publication . All prices are before any applicable code.
Mounjaro bundles: what they are and when they can save you money
A Mounjaro bundle allows you to order two or three pens in a single purchase. This typically provides an 8 or 12 week supply and may cost less than buying the same pens individually.
Bundles can be a good option for people who are established on a dose that their prescriber has confirmed is appropriate. They may help reduce the cost per week and mean you need to reorder less often.
Before choosing a bundle, your prescriber will assess whether it is suitable for your treatment plan. The right option depends on your current dose, how well you are responding to treatment, and whether any dose changes are expected.
| Bundle | Pens / supply | Price | First-order price |
|---|---|---|---|
| Intro Duo (2.5mg + 5mg) | 2 pens · 8 weeks | £339.99 | £299.99 |
| Progress Duo (5mg + 7.5mg) | 2 pens · 8 weeks | £409.99 | £369.99 |
| Intro Trio (2.5mg → 7.5mg) | 3 pens · 12 weeks | £574.99 | £534.99 |
| Progress Trio (5mg → 10mg) | 3 pens · 12 weeks | £674.99 | £634.99 |
Remove entirely before publication .
Single pen vs bundle: a quick decision guide
A single pen may be the better choice if you:
- Are new to Mounjaro.
- Are still increasing your dose as part of your treatment plan.
- Prefer to review your progress with your prescriber each month before ordering again.
A bundle may be worth considering if you:
- Are established on a dose that your prescriber has confirmed is appropriate.
- Want to reduce your average weekly treatment cost.
- Expect to continue on your current treatment plan.
As a general guide, a 12 week Trio bundle spreads the cost over three months and may reduce the average cost per week compared with buying the same pens separately. Only order multiple pens if they have been approved by your prescriber. Do not stock up on a dose that has not yet been prescribed for you, and always store Mounjaro according to the manufacturer's instructions.
Pros and cons of Mounjaro bundles
Benefits
- May offer a lower average weekly cost.
- Fewer repeat orders to manage.
- Can provide added convenience by reducing the need to reorder as often.
Things to consider
- Higher upfront cost.
- Less flexibility if your prescriber decides to change your treatment plan.
- More medication to store correctly.
What is included in the price, and what hidden fees should you look out for?
A transparent price should include the medication, your online clinical assessment, an independent prescriber review, dispensing, and tracked delivery.
Before switching to a new provider, it is worth checking:
- Whether the consultation or prescription is charged separately.
- Whether temperature controlled delivery costs extra.
- Whether the advertised "from" price only applies to the starting dose.
- Whether follow up reviews are included in the price.
At EverydayMeds, these services are included in the listed price, with no hidden prescription fees.
How ordering works, and how your medicine is delivered
After you complete your free online consultation, an independent prescriber will review your medical information to decide whether Mounjaro is suitable for you. This review is usually completed within around three working days. Some providers may also offer a faster express service for eligible orders.
If your prescription is approved, your medication will be dispensed by a GPhC registered UK pharmacy and delivered in insulated, temperature controlled packaging.
Because tirzepatide is temperature sensitive, it should be stored in a refrigerator at 2°C to 8°C and protected from light. Always follow the storage instructions in your Patient Information Leaflet, along with any advice provided by your prescriber or pharmacist.
If an injection isn't right for you, oral options exist too: read about the Wegovy Pill as an oral GLP-1 treatment, and your prescriber can help you decide which route suits you.
Questions to ask before switching providers
Before choosing a new provider, it is worth asking a few important questions:
- Is the pharmacy GPhC registered, and does an independent prescriber carry out the clinical assessment?
- Is the medication genuine Eli Lilly Mounjaro, dispensed by a UK pharmacy?
- If it is clinically appropriate, can I continue on my current dose?
- Are the consultation, prescription, and delivery included in the price?
- Is my next dose currently in stock, and how quickly can it be dispatched?
- Is the medication delivered in temperature controlled packaging, and what support is available if I experience side effects?
Key takeaways
- You can switch Mounjaro providers in the UK, but you will need a new clinical assessment by an independent prescriber.
- If it is clinically appropriate, you may be able to continue on your current dose rather than starting again.
- When comparing providers, look at the total cost, the clinical service, and the level of ongoing support, not just the advertised price.
- Mounjaro bundles may help reduce the average weekly cost for people who are established on a dose that has already been approved by their prescriber. Single pens are often a better choice if you are still increasing your dose or want greater flexibility.
- Mounjaro is made by Eli Lilly, is licensed by the MHRA, and is supported by evidence from the SURMOUNT clinical trial programme.
- Mounjaro should only be used under the supervision of a qualified prescriber, and individual results will vary.
Medical disclaimer
This article is provided for general information only. It is not medical advice, a diagnosis, or a treatment recommendation, and it should not replace advice from a qualified healthcare professional.
Mounjaro (tirzepatide) is a prescription only medicine and should only be used under the supervision of a registered prescriber following an individual clinical assessment. It is not suitable for everyone.
Do not start, stop, switch, or change your dose based on this article alone. The clinical results mentioned are average outcomes from published studies carried out under specific conditions and should not be viewed as a guarantee of individual results. Results vary from person to person.
Always read the Patient Information Leaflet supplied with your medication and speak to your prescriber or pharmacist if you have any questions about your treatment, other medicines you are taking, or possible side effects.
If you experience a serious reaction, seek medical attention immediately. Suspected side effects can also be reported through the MHRA Yellow Card Scheme.
This content is based on publicly available UK guidance from organisations including the MHRA, NICE, and the NHS. It should be reviewed by a suitably qualified clinician before publication.
